Mark has over thirty years of practical experience in the discovery of novel treatments for human disease, originally in academia but mostly in industry. At Pfizer, he was responsible for research into neurodegenerative diseases in the UK, where he left to set up Cambridge Drug Discovery in 1997.
Since then, Mark has helped raise over £200 million for a series of early-stage life sciences companies and served on the boards of multiple therapeutics and diagnostics companies worldwide. He has worked with teams to out licence therapeutic assets over the last twenty years for upfront payments, milestones and future royalties exceeding £1.5 billion.
Mark has a PhD awarded from the University of Cambridge in 1987 and has also taught at the Universities of Basel and Kent. He has published over ninety articles in peer-reviewed scientific journals and in the commercial trade press since 1984.